ORGO:NASDAQOrganogenesis Holdings Inc. Analysis
Data as of 2026-08-17 - not real-time
$1.72
Latest Price
9/10Risk
Risk Level: High
Executive Summary
At $1.72, Organogenesis Holdings Inc. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has lost 30.8% over the past 30 days. With RSI at 25.9 the momentum picture is oversold, alongside a bearish MACD signal. Recent trading has carved out support near $1.54 and resistance around $2.69.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 16.6% above where the shares trade now. Revenue is contracting at 56.7% on a -18.4% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 91.3%, a beta of 1.31 and a maximum drawdown of 73.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 3/10 conviction on the long call.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 16.6% above where the shares trade now. Revenue is contracting at 56.7% on a -18.4% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 91.3%, a beta of 1.31 and a maximum drawdown of 73.8%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 3/10 conviction on the long call.
Top Market Events
CANTON, Mass., Aug. 06, 2026 GLOBE NEWSWIRE -- Organogenesis Holdings Inc. Nasdaq: ORGO , a leading regenerative...CANTON, Mass., July 09, 2026 GLOBE NEWSWIRE -- Organogenesis Holdings Inc. Nasdaq: ORGO , a leading regenerative...Detailed price information for Organogenesis Holdings Inc ORGO-Q from The Globe and Mail including charting and trades.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 5/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 25.9 signals oversold conditions
- Trading below the 200-day average of 3.34
Medium Term
1–3 yearsCautious
Model confidence: 4/10
Key Factors
- Short-term moving averages stacked below long-term ones
- RSI at 25.9 signals oversold conditions
- Trading below the 200-day average of 3.34
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Negative profit margin of -18.4%
- Analyst targets imply +16.6% versus the current price
- Negative return on equity of -25.9%
Key Metrics & Analysis
Financial Health
Revenue Growth-56.70%
Profit Margin-18.40%
P/E Ratio-5.5
ROE-25.92%
ROA-4.11%
Debt/Equity23.24
P/B Ratio1.5
Op. Cash Flow$32.0M
Free Cash Flow$28.4M
Industry P/E29.9
Technical Analysis
TrendBearish
RSI25.9
Support$1.54
Resistance$2.69
MA 20$2.23
MA 50$2.36
MA 200$3.34
MACDBearish
VolumeIncreasing
Fear & Greed Index94.23
Valuation
Fair Value$2.69
Target Price$2.00
Upside/Downside16.62%
GradeFair
TypeBlend
Risk Assessment
Beta1.31
Volatility91.29%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.